您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > SX-3228
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SX-3228
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SX-3228图片
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
SX-3228是一种选择性苯二氮卓类(benzodiazepine1,BZ1)受体激动剂,IC50为17nM。

Animal experiment:

Rats[1]Twelve male Wistar rats (350-380 g) are used. Subcutaneous (sc) injections are given in a final volume of 1.0 mL/kg. All rats are given the corresponding volume of control solution (saline+Tween-80) in the control sessions. Following sc injection, a 6-h sleep recording is started at approximately 8:00 a.m. At least 4 days are allowed to elapse between injections to avoid long-lasting and rebound effects on sleep. The effects of SX-3228 0.5-2.5 mg/kg are studied in one group of animals (N=6) during the light phase of the 12-h light:12-h dark cycle, starting 1 h after the beginning of the light period. Polysomnographic recordings are started immediately after control solution or drug administration. Each rat receives all four treatments (control, and 0.5, 1.0, 2.5 mg/kg SX-3228).

产品描述

SX-3228 is a selective benzodiazepine1 (BZ1) receptor agonist with an IC50 of 17 nM.

SX-3228 is a selective ligand for the BZ1 receptor. Among the BZ-receptor subtypes, SX-3228 preferentially binds to the BZ1 receptor (IC50=17 nM). It has very weak affinity for the BZ2 receptor (spinal cord: IC50=127 nM), and virtually no affinity for the peripheral type BZ receptor (kidney: IC50>10000 nM). A compound with similar selectivity, SX-3228 has been shown to bind to BZ receptors, but not to dopamine (D1, D2), serotonin (5-HT1, 5-HT2 and 5-HT3 subtypes), noradrenaline (α1, α2, β), GABA or acetylcholine (muscarinic) subtypes[1].

Administration of 0.5-2.5 mg/kg SX-3228 to rats during the light phase induces a significant reduction of rapid-eye-movement sleep (REMS) (P<0.05) during the third recording hour. Administration of SX-3228 (0.5-2.5 mg/kg) at the beginning of the dark period significantly and dose-dependently reduces waking (W) and increases slow wave sleep (SWS) during the 6-h recording period (P<0.05-0.01); however, significant changes during the last recording hour are restricted to the 2.5 mg/kg dose (P<0.01)[1].

[1]. Alvari?o F, et al. Effect of SX-3228, a selective ligand for the BZ1 receptor, on sleep and waking during the light-dark cycle in the rat. Braz J Med Biol Res. 1999 Aug;32(8):1007-14.